MiNA Therapeutics Limited
minatx.com
Actively hiring
Financial Services
Health Care
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
NS Pharma Announces Research Alliance with MiNA Therapeutics to Develop Therapies for Rare Diseases of the Central Nervous System
NS Pharma, Inc. (NS Pharma) announced that its parent company, Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) - headquartered in Kyoto, Japan, entered into a joint research agreement with MiNA Therapeutics - headquartered in London, United Kingdom, to develo
Read more
Report
Lilly and MiNA Therapeutics Announce saRNA Research Collaboration
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and MiNA Therapeutics Limited, a pioneer in RNA activation therapeutics, today announced a global research...
Read more
Report
MiNA Therapeutics Secures £23 Million Series A Financing to Advance First-in-Class Activating RNA-Based Therapeutics
Read more
Report
Study published in Hepatology demonstrates ability of saRNA to improve liver function and inhibit carcinogenesis in vivo
MiNA Therapeutics, a biotechnology company developing RNA for transcriptional gene activation, announced today that its academic co-founders published a study in Hepatology demonstrating that saRNA therapeutics induced in vivo production of mRNA and prote
Read more
Report
Marina Biotech and MiNA Therapeutics Announce License Agreement for the Development of saRNA-based Therapeutics
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, and MiNA Therapeutics Limited, the pioneer in RNA activation therapeutics, announced today that they have entered into a lice
Read more
Report
European Patent Office Grants Broad RNAa Patent from Corey Estate Exclusively Licensed by MiNA Therapeutics
MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today that the European Patent Office (EPO) has granted a patent in the Corey patent estate (EP Patent Number 2641970). This patent stems from the pioneering RNAa research performed
Read more
Report
MiNA Completes Exclusive License Agreement with University of California San Francisco
MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today that it has completed an exclusive license agreement with The Regents of the University of California relating to intellectual property rights developed by the Li lab at UC San
Read more
Report
MiNA Therapeutics Announces AASLD Liver Meeting Presentation on Lead Program Demonstrating Reversal of Liver Failure in Animal Model
MiNA Therapeutics, the pioneer in RNA activation therapeutics, today announced the presentation of pre-clinical data on its MTL-CEBPA program in which the compound was shown to improve several markers of liver function in a rat model of liver failure. MTL
Read more
Report
David Blakey Ph.D. joins MiNA Therapeutics as Chief Scientific Officer
MiNA Therapeutics, the pioneer in RNA activation therapeutics, today announced the appointment of David Blakey Ph.D. as Chief Scientific Officer. Dr. Blakey will lead the Company's research and development activities. "David brings to MiNA a depth of scie
Read more
Report
MiNA Therapeutics Presents Data Demonstrating Survival Benefit of MTL-CEBPA in Animal Model of Liver Failure at AASLD Liver Meeting
MiNA Therapeutics, the pioneer in RNA activation therapeutics, today announced the presentation of pre-clinical data on its MTL-CEBPA program in which the compound was shown to improve survival in a rat model of liver failure. MTL-CEBPA is the first devel
Read more
Report
Show more news